1
|
Bonnet B, de Baère T, Beunon P, Feddal A, Tselikas L, Deschamps F. Robotic-assisted CT-guided percutaneous thermal ablation of abdominal tumors: An analysis of 41 patients. Diagn Interv Imaging 2024; 105:227-232. [PMID: 38368177 DOI: 10.1016/j.diii.2024.01.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2023] [Revised: 01/15/2024] [Accepted: 01/18/2024] [Indexed: 02/19/2024]
Abstract
PURPOSE Robotic assistance is rapidly evolving and may help physicians optimize needle guidance during percutaneous interventions. The purpose of the study was to report feasibility, safety, accuracy, immediate clinical success and short-term local tumor control after robotic-assisted computed tomography (CT)-guided thermal ablation of abdominal tumors. MATERIALS AND METHODS Forty-one patients who underwent percutaneous thermal ablation of abdominal tumors using robotic-assisted CT-guided were included. All ablations were performed with robotic assistance, using an optically-monitored robotic system with a needle guide sent to preplanned trajectories defined on three-dimensional-volumetric CT acquisitions with respiration monitoring. Endpoints were technical success, safety, distance from needle tip to planned trajectory and number of needle adjustments, and complete ablation rate. RESULTS Forty-one patients (31 men; mean age, 66.7 ± 9.9 [standard deviation (SD)] years [age range: 41-84 years]) were treated for 48 abdominal tumors, with 79 planned needles. Lesions treated were located in the liver (23/41; 56%), kidney (14/41;34%), adrenal gland (3/41; 7%) or retroperitoneum (1/41; 2%). Technical success was achieved in 39/41 (95%) patients, and 76/79 (96%) needle insertions. The mean lateral distance between the needle tip and planned trajectory was 3.2 ± 4.5 (SD) mm (range: 0-20 mm) before adjustments, and the mean three-dimensional distance was 1.6 ± 2.6 (SD) mm (range: 0-13 mm) after 29 manual depth adjustments (29/78; 37%) and 33 lateral adjustments (33/78; 42%). Two (2/79; 3%) needles required complete manual reinsertion. One grade 3 complication was reported in one patient (1/41; 2%). The overall clinical success rate was 100%. The 3-month local tumor control rate (progression free survival) was 95% (38/41). CONCLUSION These results provide further evidence on the use of robotic-assisted needle insertion regarding feasibility, safety, and accuracy, resulting in effective percutaneous thermal ablation of abdominal tumors.
Collapse
Affiliation(s)
- Baptiste Bonnet
- Centre d'Investigation Clinique BIOTHERIS, INSERM CIC1428, Radiologie Interventionnelle; Laboratoire de Recherche Translationnelle en Immunothérapie (LRTI), INSERM U1015, 94805 Villejuif, France
| | - Thierry de Baère
- Centre d'Investigation Clinique BIOTHERIS, INSERM CIC1428, Radiologie Interventionnelle; Laboratoire de Recherche Translationnelle en Immunothérapie (LRTI), INSERM U1015, 94805 Villejuif, France; Gustave Roussy, Service d'Imagerie Thérapeutique, Département d'Anesthésie, Chirurgie et Interventionnel (DACI), 94805 Villejuif, France; Faculté de Médecine, Paris-Saclay Université, 94270 Le Kremlin Bicêtre, France.
| | - Paul Beunon
- Centre d'Investigation Clinique BIOTHERIS, INSERM CIC1428, Radiologie Interventionnelle; Laboratoire de Recherche Translationnelle en Immunothérapie (LRTI), INSERM U1015, 94805 Villejuif, France
| | - Adlane Feddal
- Centre d'Investigation Clinique BIOTHERIS, INSERM CIC1428, Radiologie Interventionnelle; Laboratoire de Recherche Translationnelle en Immunothérapie (LRTI), INSERM U1015, 94805 Villejuif, France
| | - Lambros Tselikas
- Centre d'Investigation Clinique BIOTHERIS, INSERM CIC1428, Radiologie Interventionnelle; Laboratoire de Recherche Translationnelle en Immunothérapie (LRTI), INSERM U1015, 94805 Villejuif, France; Gustave Roussy, Service d'Imagerie Thérapeutique, Département d'Anesthésie, Chirurgie et Interventionnel (DACI), 94805 Villejuif, France; Faculté de Médecine, Paris-Saclay Université, 94270 Le Kremlin Bicêtre, France
| | - Frédéric Deschamps
- Centre d'Investigation Clinique BIOTHERIS, INSERM CIC1428, Radiologie Interventionnelle; Laboratoire de Recherche Translationnelle en Immunothérapie (LRTI), INSERM U1015, 94805 Villejuif, France; Gustave Roussy, Service d'Imagerie Thérapeutique, Département d'Anesthésie, Chirurgie et Interventionnel (DACI), 94805 Villejuif, France
| |
Collapse
|
2
|
Petersson RD, Fode M, Niebuhr MH, Rashu BS, Thomsen FF. Robot-assisted partial nephrectomy in patients aged 75 years or older - comparing the risk of complications with their younger counterparts. Aging Clin Exp Res 2024; 36:107. [PMID: 38714631 PMCID: PMC11076407 DOI: 10.1007/s40520-024-02751-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2024] [Accepted: 03/28/2024] [Indexed: 05/10/2024]
Abstract
BACKGROUND & AIM More elderly patients are diagnosed with kidney tumors where partial nephrectomy is technically possible. We investigated whether patients ≥ 75 years old had an increased risk of complications following robot-assisted partial nephrectomy (RAPN) compared to younger patients. METHODS Retrospective, consecutive study including patients who underwent RAPN between May 2016 - April 2023. Preoperative data, operative data and complications within 90 days were recorded by patient record review. Complications were classified according to Clavien-Dindo (CD). RESULTS 451 patients underwent RAPN and a postoperative complication was recorded in 131 (29%) patients of which 28 (6%) were CD ≥ III. Any postoperative complication was recorded in 24/113 patients (21%) < 55 years, 40/127 patients (31%) 55-64 years, 45/151 patients (42%) 65-74 years, and 22/60 patients (37%) ≥ 75 years. Comparable numbers for a CD ≥ III postoperative complication were 2/113 (2%) < 55 years, 6/127 (7%) 55-64 years, 12/151 (8%) 65-74 years, and 5/60 (8%) ≥ 75 years. In multivariate logistic regression analysis, patients ≥ 75 years had a non-significant increased risk of complications when controlling for preoperative variables (OR 1.82 [95% CI 0.80-4.13]) or perioperative variables (OR 1.98 [95% CI 0.86-4.58]) compared to patients < 55 years. Two patients died postoperatively. Both were ≥ 75 years (2/60, 3%). DISCUSSION AND CONCLUSIONS Selected patients ≥ 75 years can undergo RAPN without a significantly increased risk of postoperative complications. However, a mortality rate of 3% in this age group indicates that these patients are frail when postoperative complications occur.
Collapse
Affiliation(s)
- Rasmus D Petersson
- Department of Urology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Herlev, Denmark
- Department of Urology, Zealand University Hospital, Roskilde, Denmark
| | - Mikkel Fode
- Department of Urology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Herlev, Denmark.
| | - Malene H Niebuhr
- Department of Urology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Herlev, Denmark
| | - Badal S Rashu
- Department of Urology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Herlev, Denmark
| | - Frederik F Thomsen
- Department of Urology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Herlev, Denmark
| |
Collapse
|
3
|
Garnier C, Ferrer L, Vargas J, Gallinato O, Jambon E, Le Bras Y, Bernhard JC, Colin T, Grenier N, Marcelin C. A CT-Based Clinical, Radiological and Radiomic Machine Learning Model for Predicting Malignancy of Solid Renal Tumors (UroCCR-75). Diagnostics (Basel) 2023; 13:2548. [PMID: 37568911 PMCID: PMC10417436 DOI: 10.3390/diagnostics13152548] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2023] [Revised: 07/05/2023] [Accepted: 07/25/2023] [Indexed: 08/13/2023] Open
Abstract
BACKGROUND Differentiating benign from malignant renal tumors is important for patient management, and it may be improved by quantitative CT features analysis including radiomic. PURPOSE This study aimed to compare performances of machine learning models using bio-clinical, conventional radiologic and 3D-radiomic features for the differentiation of benign and malignant solid renal tumors using pre-operative multiphasic contrast-enhanced CT examinations. MATERIALS AND METHODS A unicentric retrospective analysis of prospectively acquired data from a national kidney cancer database was conducted between January 2016 and December 2020. Histologic findings were obtained by robotic-assisted partial nephrectomy. Lesion images were semi-automatically segmented, allowing for a 3D-radiomic features extraction in the nephrographic phase. Conventional radiologic parameters such as shape, content and enhancement were combined in the analysis. Biological and clinical features were obtained from the national database. Eight machine learning (ML) models were trained and validated using a ten-fold cross-validation. Predictive performances were evaluated comparing sensitivity, specificity, accuracy and AUC. RESULTS A total of 122 patients with 132 renal lesions, including 111 renal cell carcinomas (RCCs) (111/132, 84%) and 21 benign tumors (21/132, 16%), were evaluated (58 +/- 14 years, men 74%). Unilaterality (100/111, 90% vs. 13/21, 62%; p = 0.02), necrosis (81/111, 73% vs. 8/21, 38%; p = 0.02), lower values of tumor/cortex ratio at portal time (0.61 vs. 0.74, p = 0.01) and higher variation of tumor/cortex ratio between arterial and portal times (0.22 vs. 0.05, p = 0.008) were associated with malignancy. A total of 35 radiomics features were selected, and "intensity mean value" was associated with RCCs in multivariate analysis (OR = 0.99). After ten-fold cross-validation, a C5.0Tree model was retained for its predictive performances, yielding a sensitivity of 95%, specificity of 42%, accuracy of 87% and AUC of 0.74. CONCLUSION Our machine learning-based model combining clinical, radiologic and radiomics features from multiphasic contrast-enhanced CT scans may help differentiate benign from malignant solid renal tumors.
Collapse
Affiliation(s)
- Cassandre Garnier
- Department of Imaging and Interventional Radiology, Hôpital Pellegrin, Place Amélie-Raba-Léon, 33076 Bordeaux, France
| | - Loïc Ferrer
- SOPHiA GENETICS, Multimodal Research, Cité de la Photonique—Bâtiment GIENAH, 11 Avenue de Canteranne, 33600 Pessac, France; (L.F.); (J.V.); (O.G.); (T.C.)
| | - Jennifer Vargas
- SOPHiA GENETICS, Multimodal Research, Cité de la Photonique—Bâtiment GIENAH, 11 Avenue de Canteranne, 33600 Pessac, France; (L.F.); (J.V.); (O.G.); (T.C.)
| | - Olivier Gallinato
- SOPHiA GENETICS, Multimodal Research, Cité de la Photonique—Bâtiment GIENAH, 11 Avenue de Canteranne, 33600 Pessac, France; (L.F.); (J.V.); (O.G.); (T.C.)
| | - Eva Jambon
- Department of Imaging and Interventional Radiology, Hôpital Pellegrin, Place Amélie-Raba-Léon, 33076 Bordeaux, France
| | - Yann Le Bras
- Department of Imaging and Interventional Radiology, Hôpital Pellegrin, Place Amélie-Raba-Léon, 33076 Bordeaux, France
| | | | - Thierry Colin
- SOPHiA GENETICS, Multimodal Research, Cité de la Photonique—Bâtiment GIENAH, 11 Avenue de Canteranne, 33600 Pessac, France; (L.F.); (J.V.); (O.G.); (T.C.)
| | - Nicolas Grenier
- Department of Imaging and Interventional Radiology, Hôpital Pellegrin, Place Amélie-Raba-Léon, 33076 Bordeaux, France
| | - Clément Marcelin
- Department of Imaging and Interventional Radiology, Hôpital Pellegrin, Place Amélie-Raba-Léon, 33076 Bordeaux, France
| |
Collapse
|
4
|
Bodard S, Boudhabhay I, Dariane C, Delavaud C, Guinebert S, Joly D, Timsit MO, Mejean A, Verkarre V, Hélénon O, Richard S, Correas JM. Percutaneous Thermal Ablation for Renal Tumors in Patients with Birt–Hogg–Dubé Syndrome. Cancers (Basel) 2022; 14:cancers14204969. [PMID: 36291753 PMCID: PMC9599652 DOI: 10.3390/cancers14204969] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2022] [Revised: 10/03/2022] [Accepted: 10/07/2022] [Indexed: 11/16/2022] Open
Abstract
BHD syndrome is characterized by an increased risk of bilateral and multifocal renal cell carcinoma (RCCs), but is rarely metastatic. Our report aims to analyze the outcome of patients with BHD syndrome who underwent percutaneous thermal ablation (TA). The present report included six BHD syndrome patients (five men) with a mean age of 66 ± 11 (SD) years who had a proven germline FLCN gene mutation and underwent TA for a renal tumor. Nineteen renal tumors (median two tumors per patient; range: 1–3), including seven chromophobe RCCs, five clear-cell RCCs, four papillary RCCs, two clear-cell papillary RCC, and one hybrid oncocytic/chromophobe tumor were treated in 14 ablation sessions. The mean size of the tumors was 21 ± 11 (SD) mm (median: 20 mm; interquartile range (IQR): 14–25 mm) for a mean volume of 7 ± 11 (SD) mL (median: 3; IQR: 1–5 mL). Technical success was achieved in all ablation sessions (primary success rate, 100%). The procedure was well tolerated under conscious sedation with no significant Clavien–Dindo complication (grade 2, 3, 4). All patients were alive with no distant metastasis during a median follow-up period of 74 months (range: 33–83 months). No local tumor progression was observed. The mean decrease in estimated glomerular filtration rate was 8 mL/min/1.73 m2. No patients required dialysis or renal transplantation. In this case series, percutaneous TA appeared as a safe and efficient nephron-sparing treatment for treating RCCs associated with BHD syndrome, even in the case of advanced chronic kidney disease.
Collapse
Affiliation(s)
- Sylvain Bodard
- AP-HP, Hôpital Necker Enfants Malades, Service d’Imagerie Adulte, F-75015 Paris, France
- Université de Paris Cité, F-75006 Paris, France
- Sorbonne Université, CNRS, INSERM Laboratoire d’Imagerie Biomédicale, F-75005 Paris, France
- Correspondence: ; Tel.: +33-618816210
| | - Idris Boudhabhay
- Université de Paris Cité, F-75006 Paris, France
- AP-HP, Hôpital Necker Enfants Malades, Service de Néphrologie–Transplantation Adulte, F-75015 Paris, France
| | - Charles Dariane
- Université de Paris Cité, F-75006 Paris, France
- AP-HP, Hôpital Européen Georges Pompidou, Service d’Urologie, F-75015 Paris, France
| | - Christophe Delavaud
- AP-HP, Hôpital Necker Enfants Malades, Service d’Imagerie Adulte, F-75015 Paris, France
| | - Sylvain Guinebert
- AP-HP, Hôpital Necker Enfants Malades, Service d’Imagerie Adulte, F-75015 Paris, France
- Université de Paris Cité, F-75006 Paris, France
| | - Dominique Joly
- Université de Paris Cité, F-75006 Paris, France
- AP-HP, Hôpital Necker Enfants Malades, Service de Néphrologie–Transplantation Adulte, F-75015 Paris, France
| | - Marc-Olivier Timsit
- Université de Paris Cité, F-75006 Paris, France
- AP-HP, Hôpital Necker Enfants Malades, Service de Néphrologie–Transplantation Adulte, F-75015 Paris, France
- Réseau National pour Cancers Rares de l’Adulte PREDIR labellisé par l’INCa/AP-HP, Hôpital Bicêtre, F-94270 Le Kremlin-Bicêtre, France
| | - Arnaud Mejean
- Université de Paris Cité, F-75006 Paris, France
- AP-HP, Hôpital Européen Georges Pompidou, Service d’Urologie, F-75015 Paris, France
- Réseau National pour Cancers Rares de l’Adulte PREDIR labellisé par l’INCa/AP-HP, Hôpital Bicêtre, F-94270 Le Kremlin-Bicêtre, France
| | - Virginie Verkarre
- Université de Paris Cité, F-75006 Paris, France
- Réseau National pour Cancers Rares de l’Adulte PREDIR labellisé par l’INCa/AP-HP, Hôpital Bicêtre, F-94270 Le Kremlin-Bicêtre, France
- AP-HP, Hôpital Européen Georges Pompidou, Service d’Anatomie et Cytologie Pathologiques, F-75015 Paris, France
| | - Olivier Hélénon
- AP-HP, Hôpital Necker Enfants Malades, Service d’Imagerie Adulte, F-75015 Paris, France
- Université de Paris Cité, F-75006 Paris, France
| | - Stéphane Richard
- Réseau National pour Cancers Rares de l’Adulte PREDIR labellisé par l’INCa/AP-HP, Hôpital Bicêtre, F-94270 Le Kremlin-Bicêtre, France
- Ecole Pratique des Hautes Etudes, EPHE, Université PSL, F-75014, France
- UMR 9019-CNRS, Gustave Roussy Cancer Campus, F-94800 Villejuif, France
- Service d’Urologie, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, F-94270 Le Kremlin-Bicêtre, France
| | - Jean-Michel Correas
- AP-HP, Hôpital Necker Enfants Malades, Service d’Imagerie Adulte, F-75015 Paris, France
- Université de Paris Cité, F-75006 Paris, France
- Sorbonne Université, CNRS, INSERM Laboratoire d’Imagerie Biomédicale, F-75005 Paris, France
- Réseau National pour Cancers Rares de l’Adulte PREDIR labellisé par l’INCa/AP-HP, Hôpital Bicêtre, F-94270 Le Kremlin-Bicêtre, France
| |
Collapse
|
5
|
CT evaluation of patent artery after percutaneous cryoablation of renal cell carcinoma. Diagn Interv Imaging 2021; 102:753-758. [PMID: 34144934 DOI: 10.1016/j.diii.2021.06.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2021] [Revised: 05/29/2021] [Accepted: 06/01/2021] [Indexed: 11/20/2022]
Abstract
PURPOSE The purpose of this retrospective study was to determine the incidence of persistent patent artery after percutaneous cryoablation of renal cell carcinoma (RCC) and the relationship between patent arteries one month after cryoablation and early tumor progression. MATERIALS AND METHODS One hundred and fifty-nine patients (112 men, 47 women; mean age, 63.6±14.6 [SD] years; age range: 21-91 years) who underwent percutaneous cryoablation for 186 RCCs (mean diameter, 1.9±0.6 [SD] cm; range: 0.7-4.0cm) were retrospectively included. After cryoablation, patients underwent contrast-enhanced computed tomography (CT) with ≤2-mm slice thickness within one week from cryoablation, and at one, three, and six months. The time course of patent artery in the ablated renal parenchyma after cryoablation was the primary endpoint. The relationships between patent arteries one month after cryoablation and treatment effectiveness, tumor vascularity, tumor enhancement one month after cryoablation, tumor subtype, and renal function changes were evaluated as secondary endpoints. RESULTS CT showed patent arteries in the ablated renal parenchyma within one week in 166 RCCs (89.2%), at one month in 54 RCCs (29.0%), at three months in 8 RCCs (4.3%), and at six months in 2 RCCs (1.1%). The presence of patent artery one month after cryoablation was significantly associated with tumor enhancement at the same time point (P=0.015). There was no association between patent arteries one month after cryoablation and treatment effectiveness (P=0.693). CONCLUSION Patent arteries in the ablated renal parenchyma are commonly observed on CT examination after percutaneous cryoablation of RCC. However, they gradually disappear and do not require specific treatment.
Collapse
|
6
|
Image-guided core biopsy of 2-cm or smaller renal tumors. Diagn Interv Imaging 2020; 101:715-720. [PMID: 32713757 DOI: 10.1016/j.diii.2020.07.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2020] [Revised: 07/04/2020] [Accepted: 07/08/2020] [Indexed: 12/18/2022]
Abstract
PURPOSE The purpose of this study was to retrospectively evaluate diagnostic yield, risk factors for diagnostic failure, and safety of image-guided core biopsy of renal tumors≤2cm. MATERIALS AND METHODS Eighty-four biopsies of 84 renal tumors (mean size, 1.5±0.4[SD] cm; range, 0.6-2.0cm) from 84 patients (53 men, 31 women; mean age, 61.7±12.7 [SD] years; age range, 34-87 years) were included. All adverse events (AEs) were evaluated based on the CIRSE classification. The 84 procedures were classified as diagnostic or nondiagnostic. Multiple variables related to the patients, tumors, and procedures were assessed to identify variables associated with diagnostic failure. RESULTS All 84 biopsies (100%) were technically successful, defined as penetration of the target and acquisition of some specimens. Eighty (80/84; 95.2%) biopsy procedures were diagnostic and four (4/84; 4.8%) procedures were nondiagnostic. Among 80 diagnosed renal tumors, 71/80 (88.8%) tumors were malignant (49 clear cell renal cell carcinomas [RCCs], 14 papillary RCCs, 3 chromophobe RCCs, 3 metastatic renal cancers, 1 lymphoma, and 1 unclassified RCC) and 9/80 (11.2%) lesions were benign (5 angiomyolipomas, 3 oncocytomas, and 1 inflammatory lesion). No significant differences existed in any variables between the two groups. A total of 57 (57/84; 67.9%) procedures resulted in 56 Grade 1, 2 Grade 2, and 1 Grade 3 AEs. CONCLUSION Image-guided biopsy of renal tumors≤2cm is safe and has a high diagnostic yield.
Collapse
|
7
|
Cornelis FH, Monard E, Moulin MA, Vignaud E, Laveissiere F, Ben Ammar M, Nouri-Neuville M, Barral M, Lombart B. Sedation and analgesia in interventional radiology: Where do we stand, where are we heading and why does it matter? Diagn Interv Imaging 2019; 100:753-762. [PMID: 31706790 DOI: 10.1016/j.diii.2019.10.002] [Citation(s) in RCA: 37] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2019] [Revised: 10/13/2019] [Accepted: 10/20/2019] [Indexed: 11/28/2022]
Abstract
The aims of this review were to describe the rationale and the techniques of sedation in interventional radiology, and to compile the safety and efficacy results available so far in the literature. A systematic MEDLINE/PubMed literature search was performed. Preliminary results from several studies demonstrated the feasibility, the efficacy and the safety of using sedative techniques in interventional radiology. Beyond pharmacological sedation and clinical hypnosis, digital sedation could reduce the anxiety and pain associated with interventional radiology procedures.
Collapse
Affiliation(s)
- F H Cornelis
- Department of Radiology, Tenon Hospital, Sorbonne University, AP-HP, 75020 Paris, France.
| | - E Monard
- Department of Radiology, Tenon Hospital, Sorbonne University, AP-HP, 75020 Paris, France
| | - M-A Moulin
- Department of Radiology, Tenon Hospital, Sorbonne University, AP-HP, 75020 Paris, France
| | - E Vignaud
- Department of Radiology, Tenon Hospital, Sorbonne University, AP-HP, 75020 Paris, France
| | - F Laveissiere
- Department of Radiology, Tenon Hospital, Sorbonne University, AP-HP, 75020 Paris, France
| | - M Ben Ammar
- Department of Radiology, Tenon Hospital, Sorbonne University, AP-HP, 75020 Paris, France
| | - M Nouri-Neuville
- Department of Radiology, Tenon Hospital, Sorbonne University, AP-HP, 75020 Paris, France
| | - M Barral
- Department of Radiology, Tenon Hospital, Sorbonne University, AP-HP, 75020 Paris, France
| | - B Lombart
- Saint Antoine Hospital, Sorbonne université, AP-HP, 75011 Paris, France
| |
Collapse
|
8
|
Cornelis FH, Bernhard JC. Diagnostic and interventional radiology is a milestone in the management of renal tumors in Birt-Hugg-Dubé syndrome. Diagn Interv Imaging 2019; 100:657-658. [PMID: 31285159 DOI: 10.1016/j.diii.2019.06.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- F H Cornelis
- Department of Radiology, Sorbonne Université, Tenon Hospital, 4, rue de la Chine, 75020 Paris, France.
| | - J-C Bernhard
- Department of Urology, Bordeaux University, Pellegrin Hospital, place Amélie-Raba-Léon, 33076 Bordeaux, France
| |
Collapse
|
9
|
Hélénon O, Crosnier A, Verkarre V, Merran S, Méjean A, Correas JM. Simple and complex renal cysts in adults: Classification system for renal cystic masses. Diagn Interv Imaging 2018; 99:189-218. [DOI: 10.1016/j.diii.2017.10.005] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2017] [Accepted: 09/26/2017] [Indexed: 02/08/2023]
|
10
|
Brosseau S, Gounant V, Choudat L, Pluvy J, Zalcman G, Khalil A. Xanthogranulomatous pyelonephritis complicating crizotinib treatment of an ALK-rearranged non-small-cell lung cancer. Diagn Interv Imaging 2018; 99:267-268. [PMID: 29472032 DOI: 10.1016/j.diii.2018.01.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2017] [Revised: 01/13/2018] [Accepted: 01/22/2018] [Indexed: 10/18/2022]
Affiliation(s)
- S Brosseau
- Department of Thoracic Oncology & CIC1425-CLIP2 Paris-Nord, université Paris-Diderot, hôpital Bichat-Claude Bernard, AP-HP, 46, rue Henri-Huchard, 75018 Paris, France.
| | - V Gounant
- Department of Thoracic Oncology & CIC1425-CLIP2 Paris-Nord, université Paris-Diderot, hôpital Bichat-Claude Bernard, AP-HP, 46, rue Henri-Huchard, 75018 Paris, France
| | - L Choudat
- Department of Pathology, université Paris-Diderot, hôpital Bichat-Claude Bernard, AP-HP, 46, rue Henri-Huchard, 75018 Paris, France
| | - J Pluvy
- Department of Thoracic Oncology & CIC1425-CLIP2 Paris-Nord, université Paris-Diderot, hôpital Bichat-Claude Bernard, AP-HP, 46, rue Henri-Huchard, 75018 Paris, France
| | - G Zalcman
- Department of Thoracic Oncology & CIC1425-CLIP2 Paris-Nord, université Paris-Diderot, hôpital Bichat-Claude Bernard, AP-HP, 46, rue Henri-Huchard, 75018 Paris, France
| | - A Khalil
- Department of Radiology, université Paris-Diderot, hôpital Bichat-Claude Bernard, AP-HP, 46, rue Henri-Huchard, 75018 Paris, France
| |
Collapse
|